Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2024 RAVN - Resistensovervåkning av virus i Norge
The report presents 2024 data on resistance against antivirals for treatment of influenza, SARS-CoV-2, HIV-1 infection, hepatitis B virus infection (HBV), hepatitis C virus infection (HCV), as well as infections with cytomegalovirus (CMV) and herpes simplex virus. It includes data on the usage of antiviral drugs in Norway in 2024, highlights the global spread of Highly Pathogenic Avian Influenza, and explores hepatitis E in immunosuppressed patients. Surveillance for resistance mutations to mitigate pandemic risks and strategies for controlling antiviral drug resistance are emphasized.
Publisert
Eier
Folkehelseinstituttet (FHI)
Utfører
Folkehelseinstituttet (FHI)
Forfattere
Anne-Marte Bakken Kran, Randi Lotsberg, Marit Sørvald, Hege Salvesen Blix, Karoline Bragstad, Andreas Rohringer, Marit Vedeld, Berit Aasen, Stifanos Hailemariam, Liv Røhnebæk Bjergene, Poul Engberg-Pedersen, James Muir, Emelie Aurell, Sandy Davies, Per Erik Bergh, Joakim Øverbø, Endre Vigeland og Ragnhild Tønnesen
Språk
Norsk